arrow
H

Hyoung Jin Kang

seoul national university
H指数:37
被引数:5,753

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Proteomic Signatures and Early Biomarkers Predicting Veno-Occlusive Disease in Pediatric Patients Undergoing Haploidentical HSCT with Busulfan-based Conditioning and Post-Transplant Cyclophosphamide

蛋白质组学特征和早期生物标志物预测接受白消安为基础预处理及移植后环磷酰胺治疗的异基因儿童患者中静脉闭塞病的预测研究

2025-12-220
PRE
Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study

Isatuximab联合化疗用于复发/难治性急性淋巴细胞白血病或急性髓系白血病的儿科患者:ISAKIDS研究

2025-10-300
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2025-04-160
OA
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG): RESULTS FROM PATIENTS ON A DRUG HOLIDAY (DH) IN THE PHASE 2 FIREFLY-1 TRIAL
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN THE PHASE 2 FIREFLY-1 (PNOC026) TRIAL OF THE TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY (R/R) PEDIATRIC LOW-GRADE GLIOMA (PLGG)
2024-11-110
PRE
Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

诊断和分期儿童急性淋巴细胞白血病中的中枢神经系统受累:关于其异质性的全球调查

BLOOD
IF23.1
2024-11-050
PRE
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Updated data from the iMATRIX Alectinib phase I/II open-label, multi-center study
2024-09-050
PRE
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study
2024-08-013
PRE
TYPE II RAF INHIBITOR TOVORAFENIB IN RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA (PLGG): REVERSIBLE DECREASES IN GROWTH VELOCITY IN THE PHASE 2 FIREFLY-1 TRIAL

复发/难治性小儿低级别神经胶质瘤 (PLGG) 中的II型RAF抑制剂TOVORAFENIB: 2期FIREFLY-1试验中生长速度的可逆降低

2024-06-180
OAAI
Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: Data from the iMATRIX Alectinib Phase I/II open-label, multi-center study

Alectinib在患有ALK融合的实体或CNS肿瘤的儿童和青少年中的应用: 来自iMATRIX Alectinib I/II期开放标签,多中心研究的数据

2024-04-050
PRE
A Study to Evaluate the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Patients with Pediatric Acute Lymphoblastic Leukemia Using Common Data Model-Based Real-World Data: A Retrospective Observational Study
2024-04-010
OAAI
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)

复发/难治性小儿低度神经胶质瘤中的II型RAF抑制剂tovorafenib: 2期FIREFLY-1试验 (第30卷,207页,2024)

2024-03-111
OAAI